# Prelude Therapeutics share price today (Prelude Therapeutics Incorporated, PRLD)

> Prelude Therapeutics Incorporated's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PRLD · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/prld

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $4.08 (+242.9% in a year)
- Revenue (Jun 2026): $5.7 M
- Profit (Jun 2026), incl. one-off: −$13.9 M (one-off item, see below)
- ROE: −145%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Prelude Therapeutics share price today? Prelude Therapeutics Incorporated's share price was $4.08 at the close on 4 November 2026. That is 1.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $7, and at that close it sat 53% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 1 year the share price moved +404% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Prelude Therapeutics pay? Prelude Therapeutics Incorporated pays no dividend. In the last 6 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Prelude Therapeutics on? Prelude Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Prelude Therapeutics profitable? Prelude Therapeutics Incorporated posted a net loss of $13.9 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $99.5 M. That loss is 244.1% of the quarter's revenue. The same quarter a year earlier lost $28.7 M. Read this profit with care: at −$13.9 M it is bigger than the quarter's whole revenue of $5.7 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −270.9% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Prelude Therapeutics make, and is it growing? Prelude Therapeutics Incorporated reported $5.7 M of revenue in the Jun 2026 quarter. Over 1 years it has grown 73.4% a year on average. The last full year, FY25, came in at $12.1 M. The last four reported quarters add to $22.4 M. Recent pace: the last four quarters grew +78.8% on average, against 73.4% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every $100 of sales does Prelude Therapeutics keep? Prelude Therapeutics Incorporated has almost no sales yet: FY25 revenue was $12.1 M. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Prelude Therapeutics' profit turning into cash? Prelude Therapeutics Incorporated's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $56.3 M of cash, against −$99.5 M of profit. After $67.0 K of spending on assets, free cash was −$56.4 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Prelude Therapeutics' cash go? Prelude Therapeutics Incorporated does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $831 K on assets over the last 2 years. Averaged over those years that is 3.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $831 K over the last 2 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Prelude Therapeutics' P/E ratio, and how does it compare with its own history? Prelude Therapeutics Incorporated has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Prelude Therapeutics Incorporated at 34.6× its FY25 revenue of $12.1 M. The P/E comes back here once profit turns positive. ## Is the Prelude Therapeutics business getting better or worse? Prelude Therapeutics Incorporated's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Prelude Therapeutics earn on its capital? Prelude Therapeutics Incorporated earned a ROE of −145% in FY25. Its return on capital used (ROIC) is 44.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. The key test, return on capital used minus the cost of capital: −33.7% − 10.4% = −44.1 percentage points. The 10.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Prelude Therapeutics have too much debt? Prelude Therapeutics Incorporated has total debt of $17.6 M against shareholder equity of $134 M as of Jun 2026, so its debt is 0.13× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.26 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Prelude Therapeutics shareholding pattern? 23.1% of Prelude Therapeutics Incorporated's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 10.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Prelude Therapeutics from balance-sheet trouble? For Prelude Therapeutics Incorporated, the Z-score is −3.26. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −3.26 is inside the danger zone, so the balance sheet is a real risk. ## How does Prelude Therapeutics rank in its industry? There is no score against its industry: Prelude Therapeutics Incorporated is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Prelude Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Prelude Therapeutics in size? Prelude Therapeutics is the 152nd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Oculis Holding AG, CorMedix Inc. and Prothena Corporation plc. Just below it: Editas Medicine, Inc., Altimmune, Inc. and Allogene Therapeutics, Inc. ### Biotechnology companies close in size

1. [Oculis Holding AG](https://www.sectoralpha.in/us/stocks/ocs) $449 million
2. [CorMedix Inc.](https://www.sectoralpha.in/us/stocks/crmd) $441 million
3. [Prothena Corporation plc](https://www.sectoralpha.in/us/stocks/prta) $431 million
4. Prelude Therapeutics Incorporated $420 million
5. [Editas Medicine, Inc.](https://www.sectoralpha.in/us/stocks/edit) $418 million
6. [Altimmune, Inc.](https://www.sectoralpha.in/us/stocks/alt) $412 million
7. [Allogene Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/allo) $411 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Roma Green Finance Limited](https://www.sectoralpha.in/us/stocks/roma) $390 million · Consulting Services
2. [NVE Corporation](https://www.sectoralpha.in/us/stocks/nvec) $389 million · Semiconductors
3. Prelude Therapeutics Incorporated $389 million
4. [Avalo Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/avtx) $389 million · Biotechnology
5. [Tilray Brands, Inc.](https://www.sectoralpha.in/us/stocks/tlry) $389 million · Drug Manufacturers - Specialty & Generic

## What else do people ask about Prelude Therapeutics? ### What were Prelude Therapeutics's latest quarterly results? Prelude Therapeutics Incorporated reported revenue of $5.7 M and a net loss of $13.9 M for the Jun 2026 quarter. Earnings per share were −$0.14. The operating margin was −270.9% (as of 4 November 2026). ### What is Prelude Therapeutics's market cap? Prelude Therapeutics Incorporated's market capitalisation is $420 M at a stock price of $4.08. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Prelude Therapeutics performing? Prelude Therapeutics Incorporated's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Prelude Therapeutics's stock price go up? This page does not forecast Prelude Therapeutics Incorporated's stock price. What it shows instead: the stock price is $4.08. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Prelude Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Prelude Therapeutics a stock worth studying right now? What the numbers show: Prelude Therapeutics Incorporated's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.